©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Oct 14, 2015; 21(38): 10709-10713
Published online Oct 14, 2015. doi: 10.3748/wjg.v21.i38.10709
Published online Oct 14, 2015. doi: 10.3748/wjg.v21.i38.10709
Advanced pancreatic cancer - how to choose an adequate treatment option
Eija A Korkeila, Department of Oncology, Turku University Hospital and University of Turku, 20521 Turku, Finland
Author contributions: Korkeila EA wrote this manuscript.
Conflict-of-interest statement: The author Eija A Korkeila has received a fee for serving as a speaker and an advisory board member for Abbott and Roche.
Correspondence to: Eija A Korkeila, MD, PhD, Specialist in Oncology and Radiotherapy, Department of Oncology, Turku University Hospital and University of Turku, Hämeentie 11 PB 52, 20521 Turku, Finland. eija.korkeila@tyks.fi
Telephone: +358-2-3130000 Fax: +358-2-3132850
Received: January 31, 2015
Peer-review started: February 1, 2015
First decision: April 13, 2015
Revised: May 26, 2015
Accepted: August 25, 2015
Article in press: August 25, 2015
Published online: October 14, 2015
Processing time: 255 Days and 19.7 Hours
Peer-review started: February 1, 2015
First decision: April 13, 2015
Revised: May 26, 2015
Accepted: August 25, 2015
Article in press: August 25, 2015
Published online: October 14, 2015
Processing time: 255 Days and 19.7 Hours
Core Tip
Core tip: The prognosis of metastatic pancreatic adenocarcinoma is poor. Chemotherapy is palliative at best. Some patients benefit from treatment, while some have rapidly progressing treatment-resistant disease. There are several options for single-agent and combined treatment. Some patients may even gain benefit from treatment in second and even further lines and live substantially longer than average. Why is pancreatic cancer so resistant to treatment?